Developer docs
API playgroundTry for free, no card

Search company profiles

Orasis Pharmaceuticals

Full company profile

uuid0000hyn

Namestring
Orasis Pharmaceuticals
Legal namestring
Orasis Pharmaceuticals, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company developing and commercializing prescription treatments for presbyopia, the age-related loss of near focusing ability affecting approximately 128 million people in the U.S. and nearly 2 billion globally. The company's lead and only commercial product is Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, which received FDA approval in October 2023 and was launched in the U.S. in April 2025.

Qlosi is built on the proprietary EyeQ Formulation platform, which delivers the lowest effective concentration of pilocarpine in a preservative-free, single-use vial with near-neutral pH and dual lubricating agents (hyaluronic acid and HPMC). Its mechanism is pupil modulation creating a pinhole effect and increased depth of field; clinical data from the Phase 3 NEAR-1 and NEAR-2 trials in 600+ patients showed three-line or greater gains in distance-corrected near visual acuity, no loss of distance vision, and effects lasting up to eight hours. The pupil-selective mechanism was independently validated by the Bascom Palmer Eye Institute, distinguishing Qlosi from higher-concentration pilocarpine formulations. Orasis is also pursuing ex-U.S. regulatory and commercial expansion under the brand name BESKA (Australia TGA submission filed in July 2026) and through the licensed Qlosi brand (Korea launch planned 2026 via Optus Pharmaceuticals).

The business model combines prescription pharmaceutical sales in the U.S. with international licensing economics. U.S. revenue flows through pharmacy partners BlinkRx and Medvantx (with free home delivery, First Fill Free program, and in-office dispensing in permitted states) and is driven by a sales force targeting optometrists and ophthalmologists, supported by direct-to-consumer campaigns. International revenue is generated via licensing and milestone payments plus double-digit royalties; the Korea agreement with Optus alone carries $18 million in upfront and milestone payments. The company has raised approximately $126 million in equity and structured capital across rounds from 2016 through 2024, with a $78 million Series D in October 2024 led by Arboretum Ventures and JJDC that funded the U.S. commercial launch.

Short descriptiontext

Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company that developed and commercializes Qlosi, an FDA-approved pilocarpine 0.4% eye drop for presbyopia, targeting U.S. adults 40+ through eye care professionals and pharmacy partners, with international licensing in Korea and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPonte Vedra Beach, United States
HQ citystring
Ponte Vedra Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, presbyopia treatment, prescription eye drops, pilocarpine formulations, eye care therapeutics
Industry2 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals (Presbyopia Therapeutics)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Prescription Pharmaceutical Sales
TypeOne Time License
Description

Revenue generated from sales of Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%) prescribed by eye care professionals and dispensed through pharmacy partners including BlinkRx and Medvantx, as well as in-office dispensing.

orasis-pharma.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

International licensing agreements with regional partners generate upfront payments, milestone payments, and double-digit royalties on sales. Licensing agreement with Optus Pharmaceuticals for Korea includes $18 million in upfront and milestone payments plus royalties.

orasis-pharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations
Pricing details1 tier
1Standard prescription pricing through pharmacy partners
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Quote-based pricing through BlinkRx and Medvantx pharmacy partners. First Fill Free program available for initial prescription through BlinkRx. In-office dispensing option available in states where permitted.

orasis-pharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1EyeQ Formulation
Description

Proprietary formulation technology delivering the lowest effective concentration of pilocarpine in a preservative-free eye drop with near-neutral pH and dual lubricating agents for enhanced safety and patient comfort

orasis-pharma.com
Core offering1 text field

Orasis Pharmaceuticals develops and commercializes Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for the treatment of presbyopia in adults. The product uses the proprietary EyeQ Formulation to deliver the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH solution with dual lubricating agents, improving near vision through pupil modulation. Orasis sells Qlosi through eye care professionals and pharmacy partners in the U.S., with international commercialization handled through licensing agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 3-line or more gain in distance-corrected near visual acuity (DCNVA)
+5 more records
Product overview1 text field

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company with a single core product: Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for presbyopia treatment. The product uses the proprietary EyeQ Formulation delivering the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH formulation with dual lubricating agents. Qlosi is complemented by patient support offerings including the Clear Start Kit for first prescriptions and Starter Packs for eye care professionals. The company operates a pharmacy partnership model through BlinkRx and Medvantx for prescription fulfillment. Internationally, the same formulation is marketed as BESKA in markets like Australia and Korea under licensing agreements.

Product and service1 record
1Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%
CategoryPrescription Ophthalmic Pharmaceutical (Core Product)
Description

Prescription eye drop for the treatment of presbyopia in adults. Uses the proprietary EyeQ Formulation delivering the lowest effective concentration of pilocarpine (0.4%) in a preservative-free, near-neutral pH single-use vial with dual lubricating agents (hyaluronic acid and HPMC). Improves near visual acuity through pupil modulation (pinhole effect) without impacting distance vision, with effects lasting up to 8 hours from one or two drops daily.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-07-15
Description

Submitted New Drug Application in Australia to TGA for BESKA (Qlosi) for presbyopia treatment. One of Australia's leading pharmaceutical companies with over 150 prescription and OTC medicine brands. Will be responsible for distribution and marketing in Australia.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-07
Description

Primary pharmacy partner for prescription fulfillment with integrated data-driven technology. Offers free home delivery, First Fill Free program for new prescriptions, and personalized patient support. Streamlines prescription journey management across all stakeholders.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-07
Description

Pharmacy partner providing prescription fulfillment with home delivery options for Qlosi prescriptions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-16
Description

Exclusive licensing agreement for commercialization in Korea. Includes $18 million in upfront and milestone payments plus double-digit royalties on sales. Korean-based pharmaceutical company specializing in total eye care. Plans to launch Qlosi in Korea by 2026 after regulatory approval.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Through Allergan, AbbVie commercializes Vuity (pilocarpine 1.25%), the first FDA-approved presbyopia eye drop and the most direct competitor to Orasis' Qlosi. Both target the same presbyopia patient with pilocarpine-based pupil modulation, making AbbVie the most relevant peer despite its broader ophthalmic portfolio.

TypeDirect peer
Description

Late-stage clinical ophthalmic company developing an aceclidine-based eye drop for presbyopia. Direct competitor pursuing the same patient population with a different mechanism of action, with Phase 3 data and a planned NDA submission.

TypeEmerging player
Description

Clinical-stage ophthalmic company developing BRIMOCHOL (carbachol + brimonidine) for presbyopia, with Phase 3 data. Directly competes in the presbyopia eye drop category with a non-pilocarpine mechanism.

TypeBroad incumbent
Description

Major diversified ophthalmic company with broad pharmaceutical, surgical, and consumer vision portfolios. Comparable as a larger ophthalmic incumbent with deep ECP relationships and the ability to bundle or compete with presbyopia therapies.

TypeBroad incumbent
Description

Global leader in ophthalmic pharmaceuticals, surgical, and vision care. Comparable as a large ophthalmic player with established ECP sales infrastructure and potentially a strategic acquirer or competitor for the presbyopia drop category.

TypeEmerging player
Description

Clinical and commercial ophthalmic company developing therapeutics including for presbyopia using its proprietary Optejet dispensing platform. Comparable in focus on presbyopia drug delivery and novelty in ophthalmic administration.

TypeEmerging player
Description

Late-stage ophthalmic company developing therapeutics for refractive and pupil modulation indications, including presbyopia programs. Comparable as a small-cap ophthalmic drug developer targeting eye care professionals.

TypeOthers
Description

Specialty ophthalmic company focused on interventional treatments for glaucoma and other eye disorders. Comparable as a publicly traded interventional/commercial ophthalmic peer and as a potential acquirer of complementary ophthalmic franchises.

TypeEmerging player
Description

Commercial-stage ophthalmic company with a launched prescription eye drop (Xdemvy for Demodex blepharitis). Comparable as a comparable-sized, ECP-focused ophthalmic launch story with a single specialty product.

TypeBroad incumbent
Description

Global pharmaceutical company with a significant ophthalmic franchise focused on retinal diseases and dry eye. Comparable as a large ophthalmic incumbent with potential strategic interest in the presbyopia category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orasis Pharmaceuticals

Ophthalmic Pharmaceuticals (Presbyopia Therapeutics)orasis-pharma.com

Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company that developed and commercializes Qlosi, an FDA-approved pilocarpine 0.4% eye drop for presbyopia, targeting U.S. adults 40+ through eye care professionals and pharmacy partners, with international licensing in Korea and Australia.

What Orasis Pharmaceuticals does

Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company developing and commercializing prescription treatments for presbyopia, the age-related loss of near focusing ability affecting approximately 128 million people in the U.S. and nearly 2 billion globally. The company's lead and only commercial product is Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, which received FDA approval in October 2023 and was launched in the U.S. in April 2025.

Qlosi is built on the proprietary EyeQ Formulation platform, which delivers the lowest effective concentration of pilocarpine in a preservative-free, single-use vial with near-neutral pH and dual lubricating agents (hyaluronic acid and HPMC). Its mechanism is pupil modulation creating a pinhole effect and increased depth of field; clinical data from the Phase 3 NEAR-1 and NEAR-2 trials in 600+ patients showed three-line or greater gains in distance-corrected near visual acuity, no loss of distance vision, and effects lasting up to eight hours. The pupil-selective mechanism was independently validated by the Bascom Palmer Eye Institute, distinguishing Qlosi from higher-concentration pilocarpine formulations. Orasis is also pursuing ex-U.S. regulatory and commercial expansion under the brand name BESKA (Australia TGA submission filed in July 2026) and through the licensed Qlosi brand (Korea launch planned 2026 via Optus Pharmaceuticals).

The business model combines prescription pharmaceutical sales in the U.S. with international licensing economics. U.S. revenue flows through pharmacy partners BlinkRx and Medvantx (with free home delivery, First Fill Free program, and in-office dispensing in permitted states) and is driven by a sales force targeting optometrists and ophthalmologists, supported by direct-to-consumer campaigns. International revenue is generated via licensing and milestone payments plus double-digit royalties; the Korea agreement with Optus alone carries $18 million in upfront and milestone payments. The company has raised approximately $126 million in equity and structured capital across rounds from 2016 through 2024, with a $78 million Series D in October 2024 led by Arboretum Ventures and JJDC that funded the U.S. commercial launch.

Orasis Pharmaceuticals firmographics

Firmographics
Name
Orasis Pharmaceuticals
Legal name
Orasis Pharmaceuticals, Inc.
Website
https://orasis-pharma.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company that developed and commercializes Qlosi, an FDA-approved pilocarpine 0.4% eye drop for presbyopia, targeting U.S. adults 40+ through eye care professionals and pharmacy partners, with international licensing in Korea and Australia.
Ownership category
akta.pro rank

Orasis Pharmaceuticals industry classification

Industry
Product category
Ophthalmic Pharmaceuticals (Presbyopia Therapeutics)
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmic pharmaceuticals
  • Presbyopia treatment
  • Prescription eye drops
  • Pilocarpine formulations
  • Eye care therapeutics

Where Orasis Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Ponte Vedra Beach
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Orasis Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations

Revenue model

  1. Prescription Pharmaceutical Sales: Revenue generated from sales of Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%) prescribed by eye care professionals and dispensed through pharmacy partners including BlinkRx and Medvantx, as well as in-office dispensing.
  2. Licensing and Milestone Payments: International licensing agreements with regional partners generate upfront payments, milestone payments, and double-digit royalties on sales. Licensing agreement with Optus Pharmaceuticals for Korea includes $18 million in upfront and milestone payments plus royalties.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard prescription pricing through pharmacy partners

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Orasis Pharmaceuticals product offering

Product offering

Core offering

Orasis Pharmaceuticals develops and commercializes Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for the treatment of presbyopia in adults. The product uses the proprietary EyeQ Formulation to deliver the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH solution with dual lubricating agents, improving near vision through pupil modulation. Orasis sells Qlosi through eye care professionals and pharmacy partners in the U.S., with international commercialization handled through licensing agreements.

Product overview

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company with a single core product: Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for presbyopia treatment. The product uses the proprietary EyeQ Formulation delivering the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH formulation with dual lubricating agents. Qlosi is complemented by patient support offerings including the Clear Start Kit for first prescriptions and Starter Packs for eye care professionals. The company operates a pharmacy partnership model through BlinkRx and Medvantx for prescription fulfillment. Internationally, the same formulation is marketed as BESKA in markets like Australia and Korea under licensing agreements.

Differentiator

Problem solved

Functional benefit

Brands

  • EyeQ Formulation: Proprietary formulation technology delivering the lowest effective concentration of pilocarpine in a preservative-free eye drop with near-neutral pH and dual lubricating agents for enhanced safety and patient comfort

Products and services

  • Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% Prescription eye drop for the treatment of presbyopia in adults. Uses the proprietary EyeQ Formulation delivering the lowest effective concentration of pilocarpine (0.4%) in a preservative-free, near-neutral pH single-use vial with dual lubricating agents (hyaluronic acid and HPMC). Improves near visual acuity through pupil modulation (pinhole effect) without impacting distance vision, with effects lasting up to 8 hours from one or two drops daily.

Quantifiable outcome

  • 3-line or more gain in distance-corrected near visual acuity (DCNVA)
  • +5 more outcomes

Companies that use Orasis Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

Orasis Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Orasis Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • Aspen Pharmacare AustraliamajorChannel Partner/ Reseller/ Distributor · 15 July 2026Submitted New Drug Application in Australia to TGA for BESKA (Qlosi) for presbyopia treatment. One of Australia's leading pharmaceutical companies with over 150 prescription and OTC medicine brands. Will be responsible for distribution and marketing in Australia.
  • BlinkRxcoreChannel Partner/ Reseller/ Distributor · 7 April 2025Primary pharmacy partner for prescription fulfillment with integrated data-driven technology. Offers free home delivery, First Fill Free program for new prescriptions, and personalized patient support. Streamlines prescription journey management across all stakeholders.
  • MedvantxmajorChannel Partner/ Reseller/ Distributor · 7 April 2025Pharmacy partner providing prescription fulfillment with home delivery options for Qlosi prescriptions.
  • Optus PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 16 October 2024Exclusive licensing agreement for commercialization in Korea. Includes $18 million in upfront and milestone payments plus double-digit royalties on sales. Korean-based pharmaceutical company specializing in total eye care. Plans to launch Qlosi in Korea by 2026 after regulatory approval.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Orasis Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • AbbVie (Allergan): Through Allergan, AbbVie commercializes Vuity (pilocarpine 1.25%), the first FDA-approved presbyopia eye drop and the most direct competitor to Orasis' Qlosi. Both target the same presbyopia patient with pilocarpine-based pupil modulation, making AbbVie the most relevant peer despite its broader ophthalmic portfolio.
  • Bausch + Lomb: Major diversified ophthalmic company with broad pharmaceutical, surgical, and consumer vision portfolios. Comparable as a larger ophthalmic incumbent with deep ECP relationships and the ability to bundle or compete with presbyopia therapies.
  • Alcon: Global leader in ophthalmic pharmaceuticals, surgical, and vision care. Comparable as a large ophthalmic player with established ECP sales infrastructure and potentially a strategic acquirer or competitor for the presbyopia drop category.
  • Novartis Pharmaceuticals (Ophthalmics): Global pharmaceutical company with a significant ophthalmic franchise focused on retinal diseases and dry eye. Comparable as a large ophthalmic incumbent with potential strategic interest in the presbyopia category.

Direct peers

  • LENZ Therapeutics: Late-stage clinical ophthalmic company developing an aceclidine-based eye drop for presbyopia. Direct competitor pursuing the same patient population with a different mechanism of action, with Phase 3 data and a planned NDA submission.

Emerging players

  • Visus Therapeutics: Clinical-stage ophthalmic company developing BRIMOCHOL (carbachol + brimonidine) for presbyopia, with Phase 3 data. Directly competes in the presbyopia eye drop category with a non-pilocarpine mechanism.
  • Eyenovia: Clinical and commercial ophthalmic company developing therapeutics including for presbyopia using its proprietary Optejet dispensing platform. Comparable in focus on presbyopia drug delivery and novelty in ophthalmic administration.
  • Ocuphire Pharma: Late-stage ophthalmic company developing therapeutics for refractive and pupil modulation indications, including presbyopia programs. Comparable as a small-cap ophthalmic drug developer targeting eye care professionals.
  • Tarsus Pharmaceuticals: Commercial-stage ophthalmic company with a launched prescription eye drop (Xdemvy for Demodex blepharitis). Comparable as a comparable-sized, ECP-focused ophthalmic launch story with a single specialty product.

Others

  • Glaukos Corporation: Specialty ophthalmic company focused on interventional treatments for glaucoma and other eye disorders. Comparable as a publicly traded interventional/commercial ophthalmic peer and as a potential acquirer of complementary ophthalmic franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Orasis Pharmaceuticals social profiles

Digital presence

Orasis Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orasis Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

Orasis Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orasis Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orasis Pharmaceuticals

What does Orasis Pharmaceuticals do?

Orasis Pharmaceuticals develops and commercializes Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for the treatment of presbyopia in adults. The product uses the proprietary EyeQ Formulation to deliver the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH solution with dual lubricating agents, improving near vision through pupil modulation. Orasis sells Qlosi through eye care professionals and pharmacy partners in the U.S., with international commercialization handled through licensing agreements.

Is Orasis Pharmaceuticals a public or private company?

Orasis Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Orasis Pharmaceuticals founded?

Orasis Pharmaceuticals was founded in 2018. It employs 51 to 100 people.

Where is Orasis Pharmaceuticals based?

Orasis Pharmaceuticals is headquartered in Ponte Vedra Beach, United States, in the North America region.

How does Orasis Pharmaceuticals make money?

Two revenue lines are on record. Prescription Pharmaceutical Sales are the primary driver. The others are licensing and Milestone Payments.

Who are Orasis Pharmaceuticals's main competitors?

Broad incumbents on record are AbbVie (Allergan), Bausch + Lomb, Alcon and Novartis Pharmaceuticals (Ophthalmics). LENZ Therapeutics is listed as a direct peer. Emerging players are Visus Therapeutics, Eyenovia, Ocuphire Pharma and Tarsus Pharmaceuticals. Glaukos Corporation is listed as an others.

Does Orasis Pharmaceuticals have an API?

No public API is recorded for Orasis Pharmaceuticals.

What industry is Orasis Pharmaceuticals in?

Orasis Pharmaceuticals's product category is Ophthalmic Pharmaceuticals (Presbyopia Therapeutics). Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Optometry TimesFDA approves low-dose pilocarpine hydrochloride 0.4% as a treatment for presbyopiaThe FDA has approved Orasis Pharmaceuticals' Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%) for the treatment of presbyopia, marking the first drug approval for this condition. The decision was based on phase 3 clinical trial data showing significant improvements in near visual acuity with a safety profile that preserves distance vision. This approval introduces a novel treatment option for the over 120 million Americans affected by age-related near-vision loss.PR NewswireORASIS PHARMACEUTICALS DOUBLES DOWN ON EYE CARE PROFESSIONALS, NOT TELEHEALTH, AS QLOSI® REFILLS REACH 49%¹Orasis Pharmaceuticals announced two new access options for Qlosi, a presbyopia eye drop, including a First Fill Free program through BlinkRx and in-office dispensing. Fifteen months post-launch, Qlosi refill rates reached 49%, approximately double those of dry eye therapies at retail pharmacies.BioSpaceORASIS PHARMACEUTICALS ANNOUNCES AUSTRALIA SUBMISSION OF A NEW DRUG APPLICATION FOR BESKA FOR THE TREATMENT OF PRESBYOPIAOrasis Pharmaceuticals and Aspen Australia submitted a New Drug Application to Australia's TGA for BESKA (pilocarpine hydrochloride ophthalmic solution) to treat presbyopia. The submission is supported by two Phase 3 trials with over 600 patients, showing statistically significant near visual acuity gains. Aspen will handle distribution and marketing, with approval expected next year.MorningstarORASIS PHARMACEUTICALS ANNOUNCES AUSTRALIA SUBMISSION OF A NEW DRUG APPLICATION FOR BESKA FOR THE TREATMENT OF PRESBYOPIAOrasis Pharmaceuticals and Aspen Australia submitted a New Drug Application to Australia's TGA for BESKA (pilocarpine hydrochloride ophthalmic solution) to treat presbyopia. The submission is supported by two Phase 3 trials with over 600 patients, showing statistically significant near visual acuity gains. Aspen will handle distribution and marketing, with approval and launch expected next year.YahooORASIS PHARMACEUTICALS ANNOUNCES AUSTRALIA SUBMISSION OF A NEW DRUG APPLICATION FOR BESKA FOR THE TREATMENT OF PRESBYOPIAOrasis Pharmaceuticals and Aspen Pharmacare Australia announced the submission of a New Drug Application to the Therapeutic Goods Administration for BESKA, a treatment for presbyopia. The application is supported by positive Phase 3 clinical trial data involving over 600 patients, with Aspen responsible for distribution in Australia. This marks the first regulatory submission outside the U.S. for the drug.EyeWorldEyeWorld, January 30, 2026Orasis Pharmaceuticals announced research findings that its low-dose pilocarpine formulation, Qlosi, reduces pupil diameter without significant ciliary muscle response, balancing efficacy and safety compared to higher doses. Additionally, the FDA approved an IND for Novaliq's steroid-free anti-inflammatory treatment NOV05, enabling Phase 2 trials for anterior uveitis. Orasis also highlighted a favorable safety profile with no serious adverse events reported during real-world use.PR Newswire/C O R R E C T I O N -- Orasis Pharmaceuticals/Orasis Pharmaceuticals announced new clinical data showing that Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%) is pupil selective, significantly reducing pupil diameter without statistically significant changes in ciliary muscle response in presbyopic eyes. The prospective head-to-head study, conducted by Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine on 10 subjects, found Qlosi's effects were indistinguishable from balanced salt solution control, while pilocarpine 2% showed significant ciliary muscle movement. Since launch, Qlosi has reported no cases of retinal detachment or serious adverse events across 10 months of real-world use.Eyewire+Orasis Pharmaceuticals Presents New Data Showing Qlosi Is Pupil Selective in Presbyopic EyesOrasis Pharmaceuticals announced new clinical data indicating that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% is pupil selective in presbyopic patients, significantly reducing pupil diameter without changing ciliary muscle response. The study involved ten subjects and underscored Qlosi's favorable safety profile, with no serious adverse events reported since its launch. These findings support Qlosi as a low-concentration option for presbyopia therapy that prioritizes both efficacy and safety.Eyes On EyecareNew QLOSI safety data supports drop as pupil selective for presbyopiaOrasis Pharmaceuticals presented new safety data for its presbyopia treatment QLOSI at the Hawaiian Eye and Retina 2026 meeting, confirming no reports of retinal detachments during the first ten months of commercial availability. A clinical study conducted at Bascom Palmer Eye Institute demonstrated that QLOSI's low-dose pilocarpine formulation significantly reduces pupil diameter without inducing significant ciliary muscle movement, unlike higher-concentration alternatives. These findings support the drug's safety profile and its targeted mechanism for treating adult presbyopia.PR NewswireORASIS PHARMACEUTICALS EXPANDS ACCESS TO QLOSI™ WITH NEW STARTER PACKS FOR EYE CARE PROFESSIONALS, BOLSTERING COMMERICAL ROLLOUTOrasis Pharmaceuticals announced the availability of Qlosi Starter Packs to expand access for eye care professionals and patients following the drug's successful U.S. launch in April 2025. The company reported strong market adoption with refill rates exceeding expectations and no serious adverse events since launch, while planning to scale direct-to-consumer efforts into 2026. These starter packs provide a flexible option for managing presbyopia, aiming to broaden patient experience with the FDA-approved eye drop.